Significance of Magnetic Resonance Imaging-Assessed Tumor Response for Locally Advanced Rectal Cancer Treated With Preoperative Long-Course Chemoradiation.

Autor:	Fayaz MS; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., Demian GA; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., Fathallah WM; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., Eissa HE; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., El-Sherify MS; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., Abozlouf S; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., George T; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait., Samir SM; All authors, Kuwait Cancer Control Center, Shuwaikh, Kuwait.
Jazyk:	angličtina
Zdroj:	Journal of global oncology [J Glob Oncol] 2016 Feb 10; Vol. 2 (4), pp. 216-221. Date of Electronic Publication: 2016 Feb 10 (Print Publication: 2016).
DOI:	10.1200/JGO.2015.001479
Abstrakt:	Purpose: To study the predictive and prognostic value of magnetic resonance imaging (MRI)-assessed tumor response after long-course neoadjuvant therapy for locally advanced rectal cancer. Methods: This study included 79 patients who had T3 or T4 and/or N+ rectal cancer treated with long-course neoadjuvant chemoradiation. MRI-assessed tumor regression grade (mrTRG) was assessed in 64 patients. MRIs were reviewed by the study radiologist. Surgical and pathologic reports for those who underwent surgery were reviewed. Disease-free survival (DFS) was estimated. Progression during therapy, local relapse, metastasis, and death resulting from the tumor were classified as events. Statistical significance was calculated. Results: In 11 patients, the tumor completely disappeared on MRI; that is, it had an mrTRG of 1. All but one patient, who chose deferred surgery, had a complete pathologic response (pCR), with a positive predictive value of nearly 100%. Of the 20 patients who had an mrTRG of 2 on MRI, six had a pCR. mrTRG 3, mrTRG 4, and mrTRG 5 were detected in 24, six, and three patients, respectively, of whom only one patient had a pCR. The 2-year DFS was 77%. The mrTRG was significant for DFS. The 2-year DFS was 88% for patients with a good response versus 66% for those with a poor response ( P = .046). Conclusion: MRI-assessed complete tumor response was strongly correlated with pCR and, therefore, can be used as a surrogate marker to predict absence of viable tumor cells. Our results can be used to implement use of mrTRGs in larger prospective correlative studies as a tool to select patients for whom deferred surgery may be appropriate. Also, those with a poor response may be offered further treatment options before definitive surgery. Competing Interests: Authors' disclosures of potential conflicts of interest and contributions are found at the end of this article.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Mohamed Salah FayazNo relationship to discloseGerges Attia DemianNo relationship to discloseWael Moftah FathallahNo relationship to discloseHeba El-Sayed EissaNo relationship to discloseMustafa Shawki El-SherifyNo relationship to discloseSadeq AbozloufNo relationship to discloseThomas GeorgeNo relationship to discloseSuzanne Mona SamirNo relationship to disclose
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu